Приказ основних података о документу

Genetički polimorfizam izoenzima Citohroma P450

dc.creatorRakić, Anita
dc.creatorMiljković, Branislava
dc.creatorPokrajac, Milena
dc.date.accessioned2019-09-02T10:59:17Z
dc.date.available2019-09-02T10:59:17Z
dc.date.issued2004
dc.identifier.issn0004-1963
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/527
dc.description.abstractThe aim of this review is to explain genetic basis of interindividual variability in cytochrome P450 (CYP450) dependent drug metabolism and highlight the clinical significance of different polymorphisms. Nearly all CYP450 isoenzymes involved in drug metabolism have been shown to be polymorphic, although some of them are functionally well conserved (CYP2E1 and CYP3A4) in comparison with others (CYP2D6, CYP2C19 and CYP2C9). Genetic variability in drug metabolizing enzymes can be assessed at the level of phenotype (by investigating enzyme level/activity) and/or genotype (by determining which alleles are present). Polymorphism divides a population into at least two phenotypes: individuals with deficient metabolism are termed „poor metabolizers” (PM), as compared to normal or „extensive metabolizers” (EM). In case of CYP2D6, „ultrarapide metabolizers” (UM) with extremely high enzyme activity, have also been identified. The clinical significance of particular polymorphism depends on the importance of metabolic pathway under polymorphic control, therapeutic index (TI) of a drug and its active metabolites, and incidence of the polymorphism in a particular population. Therapeutic consequences vary from increased risk of adverse reactions in PM, to therapeutic failure at standard drug doses in UM (if drug metabolites are inactive). Drug dosage, especially for narrow TI drugs, should be adjusted to the metabolic capacity of a patient , by phenotyping/genotyping prior to drug therapy.en
dc.publisherSavez farmaceutskih udruženja Srbije, Beograd
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by-sa/4.0/
dc.sourceArhiv za farmaciju
dc.subjectCYP450 isoenzymesen
dc.subjectdrug metabolismen
dc.subjectgenetic polymorphismen
dc.subjectclinical significanceen
dc.subjectizoenzimi CYP450sr
dc.subjectmetabolizam lekovasr
dc.subjectgenetički polimorfizamsr
dc.subjectklinički značajsr
dc.titleGenetic polymorphism of Cytochrome P450 isoenzymesen
dc.titleGenetički polimorfizam izoenzima Citohroma P450sr
dc.typearticle
dc.rights.licenseBY-SA
dcterms.abstractМиљковић, Бранислава; Ракић, Aнита; Покрајац, Милена; Генетички полиморфизам изоензима Цитохрома П450; Генетички полиморфизам изоензима Цитохрома П450;
dc.citation.volume54
dc.citation.issue1-2
dc.citation.spage61
dc.citation.epage76
dc.citation.other54(1-2): 61-76
dc.identifier.fulltexthttps://farfar.pharmacy.bg.ac.rs//bitstream/id/2043/525.pdf
dc.identifier.rcubhttps://hdl.handle.net/21.15107/rcub_farfar_527
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу